BASEL, Switzerland and LONDON and NEW YORK and BOSTON, March 14, 2023 (GLOBE NEWSWIRE) — Roivant Sciences ROIV announced today that it will host a live investor conference call and webcast on Wednesday, March 15 at 8:00 am ET to review topline results from the ADORING 2 study, one of two replicated Phase 3 studies on atopic dermatitis.

To participate in the call for tenders by telephone, please register online here registration link. A webcast of the conference call will also be available under Events & Presentations on the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the call.

About Roivant Sciences

Roivant’s mission is to improve patient healthcare by turning every inefficiency into an opportunity. Roivant develops transformative medicines faster by building technology and developing talent creatively, leveraging the Roivant platform to create “Vants” – flexible and focused biopharmaceutical and health technology companies.

Roivant Sciences Forward-Looking Statements

This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 as amended as amended (the “Exchange Act”), normally identified by the use of words such as “anticipate”, “believe”, “continue”, “may”, “estimate”, “expect”, “intend”, “may”, “could”, “plan”, “possible”, “potential”, “predict”, “forecast”, “should”, “would” and variations of such words or similar expressions. Such words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend that these forward-looking statements are exempt from the safe harbor principles governing forward-looking statements in…